The present invention relates to aromatic compounds of the formula I wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R a and wherein Ar may also carry 1 or 2 radicals R b ； X is N or CH； Y is O, S, -CH=N-, -CH=CH- or -N=CH-； A is CH 2 , O or S； E is CR 6 R 7 or NR 3 ； R 1 is C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, formyl or C 1 -C 3 -alkylcarbonyl； R 1a is H, C 2 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, or R 1a and R 2 together are (CH 2 ) n with n being 2 or 3, or R 1a and R 2a together are (CH 2 ) n with n being 2 or 3； R 2 and R 2a are independently of each other H, CH 3 , CH 2 F, CHF 2 or CF 3 ； R 3 is H or C 1 -C 4 -alkyl； R 6 , R 7 independently of each other are selected from H, C 1 -C 2 -alkyl and fluorinated C 1 -C 2 -alkyl； and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.本發明關於下式I之芳族化合物：其中Ar為苯基或芳族5－或6－員C－鏈結之雜芳族基，其中Ar可帶有1個Ra基，且其中Ar亦可帶有1或2個Rb基；X為N或CH；Y為O、S、－CH＝N－、－CH＝CH－或－N＝CH－；A為CH2、O或S；E為CR6R7或NR3；R1為C1－C4－烷基、C3－C4－環烷基、C3－C4－環烷基甲基、C3－C4－烯基、氟化C1－C4－烷基、氟化C3－C4－環烷基、氟化C3－C4－環烷基甲基、氟化C3－C4－烯基、甲醯基或C1－C3－烷基羰基；R1a為H、C2－C4－烷基、C3－C4－環烷基、C3－C4－烯基、氟化C1－C4－烷基、氟化C3－C4－環烷基，或R1a與R2一起為(CH2)n，且n為2或3，或R1a與R2a一起為(CH2)n，且n為2或3；R2及R2a係彼此獨立為H、CH3、CH2F、CHF2或CF3；R3為H或C1－C4－烷基；R6、R7彼此獨立選自H、C1－C2－烷基及氟化C1－C2－烷基；及其生理上可耐受之酸加成鹽。；本發明亦關於式I化合物或其醫藥可接受性鹽在製備供治療可以多巴胺D3受體配位體治療之醫療疾病之醫藥組合物之用途。
